Global Kidney Disease Drugs Market Booming Worldwide with Latest Trend and Future Scope by 2028

The global kidney disease drugs market is expected to grow at a CAGR of 4.5% during the forecast period (2022-2028). Chronic kidney disease, also known as chronic kidney failure, is a progressive loss of kidney function. Treatment techniques focus on preventing kidney damage in the early stages, while dialysis and kidney relocation is used in the later stages. Type 1 or Type 2 diabetes, hypertension, glomerulonephritis, interstitial nephritis, polycystic kidney disease, and others are all signs of persistent kidney disease.

The rising prevalence of kidney diseases and the growing demand for biopsy systems are some factors driving the growth of the market. Furthermore, the availability of various analytic tests for kidney infections has an impact on the market growth. Kidney infection is frequently referred to as a “quiet illness” as there are no symptoms in the early stages and it can go undetected, according to the National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK). It also stated that the prevalence of chronic kidney disease in the general population is nearly 14%. The extensive test for the detection of kidney disease combines a blood test and aids in determining how well the kidneys are functioning. The blood test measures the amount of creatinine in the blood, which is a secondary effect. The glomerular filtration rate, or how many milliliters of waste the kidney can divert in a second, is still up in the air. End-stage renal disease (ESRD) has a high prevalence and is spreading at an alarming rate. This rising prevalence of chronic kidney disease is supporting to drive the demand for demand for kidney disease drugs and thereby contributing to the market growth.

Market Coverage

• The market number available for – 2021-2028
• Base year- 2021
• Forecast period- 2022-2028
• Segment Covered-
  • By Drug Class
  • By Indication
  • By End-User
• Regions Covered-
  • North America
  • Europe
  • Asia-Pacific
  • Rest of the World
• Competitive Landscape- F. Hoffmann-La Roche Ltd., Pfizer Inc., and Sanofi S.A., among others.

Key questions addressed by the report

• What is the market growth rate?
• Which segment and region dominate the market in the base year?
• Which segment and region will project the fastest growth in the market?
• How COVID-19 impact the market?
  • Deviation from the pre-COVID-19 forecast
  • Most affected region and segment
• Who is the leader in the market?
• How players are addressing challenges to sustain growth?
• Where is the investment opportunity?

Global Kidney Disease Drugs Market Report by Segment

By Drug Class

• Calcium Channel Blockers
• ACE Inhibitors
• Angiotensin-II Receptor Blockers
• Diuretic
• Beta Bloockers
• Erythropoiesis-Stimulating Agents (ESAs)

By Indication

• Type 1 and Type 2 Diabetes
• High Blood Pressure

By End-User

• Hospitals
• Clinic